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Tumor cell  heterogeneity  is  an  inadequately  explored  aspect  of tumor  biology, 
especially with respect to the complexity of the host-tumor interaction. The concept 
of heterogeneity is not a new one, and many studies have focused on single phenotypic 
traits ofintratumor variants. Heterogeneity has been demonstrated for several physical 
and biochemical criteria, including morphology, karyotype, growth kinetics, anchor- 
age independence, hormone sensitivity, drug resistance, and metastatic potential (1- 
7). Fluctuation analysis of cloned tumor variants offers convincing evidence that this 
heterogeneity exists in vivo and is not merely an artifact of in vitro culture  (8).  In 
these studies, however, cells were often used that had been derived from the venerable 
survivors of tumors propagated in vitro for years, even decades. In addition, many of 
these sublines had been coaxed from cultured "tumor" lines by disruptive intervention 
into the normal cultural  life histories of the cells. One must therefore approach the 
interpretation of the results of these investigations with caution, because the cell lines 
used were sometimes of questionable biological relevance. 
Systems are known in which manipulation of cells in tissue culture results both in 
tumorigenic variants that grow in normal hosts, and also in nontumorigenic variants 
that, when placed in the proper environment, can and will grow progressively to the 
death  of the  host  (9-11).  Boon  and  Kellermann  (9)  have  isolated  cloned  tumor 
variants after in vitro mutagenesis of a  malignant teratocarcinoma cell line with N- 
methyl-N'-nitro-N-nitrosoguanidine.  These variants differ in  tumorigenicity pheno- 
type (tum÷ and turn- variants) and are immunologically cross-reactive. Collins, Patek, 
and  Cohn  (10)  have  isolated  similar  variants  after viral  or chemical  treatment  of 
normal cells. Ultraviolet (UV)1 carcinogenesis also results in the emergence in vivo of 
tumors of both phenotypes (regressors and progressors), possessing the same common 
tumor-associated antigens  (TAA), in addition  to unique tumor-specific transplanta- 
tion antigens  (TSTA;  11-14). The ability to induce both tumorigenic and nontumo- 
rigenic variants in cultured cells, and the existence of both regressor and progressor 
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UV  tumors  suggested  to us  that  heterogeneity  of tumorigenicity  phenotype  might 
preexist within tumors and may in fact be an important  influence on the growth of 
a neoplasm in a primary host. The isolation and characterization ofclonal outgrowths 
of these subpopulations might then provide a  suitable  model for the investigation of 
cellular interactions, both within tumors and within the tumor-beating host. 
We have cloned, without prior mutagenesis, a murine UV fibrosarcoma, RD-1024, 
in  soft  agarose,  and  have  isolated  and  characterized  its  daughter  clones by several 
criteria.  Although the parent  tumor is a  regressor, which is rejected  after transplan- 
tation  into normal syngeneic mice,  half of the stable clones isolated  from RD-1024 
possess a  progressor phenotype and are capable of growth in normal immunocompe- 
tent hosts. If one assumes that these progressor cell subpopulations existed within the 
parent  regressor  tumor,  then  interesting  questions  arise  concerning  their  function 
during tumor emergence and progression: (a) Why is the regressor phenotype retained 
by  RD-1024,  or in  other  words,  why  doesn't  a  progressor  cell  population  become 
dominant?  (b) Is there any influence of the regressor on the progressor phenotype, or 
of the  progressor  on  the  regressor  phenotype?  (c)  Can  the  progressor  clones  be 
implicated  in the tumorigenicity of RD-1024  in the  autochthonous  host,  and  if so, 
what  is  their  role  in  tumorigenesis?  In  this  report  we  shall  explore  some  of the 
implications of heterogeneity of tumorigenicity phenotype, confining ourselves to the 
well-characterized  UV tumor model system. 
Materials  and Methods 
Animals.  4-6-wk-old C3H/HeN female mice, obtained from Charles River Breeding Lab- 
oratories, Wilmington, Mass., were housed at a density of five to six animals per standard  7- 
×  11-inch cage and maintained on Wayne Lab Blox, Sterilizable (Allied  Mills, Chicago, Ill.) 
and acidified water ad libitum. 
Generation and  Maintenance of  UV  Tumor RD-I024.  The  induction  of RD-1024  by  UV 
irradiation of shaved C3H/HeN mice has been described in detail previously (15). This tumor 
has been classified  histologically as a  spindle cell  fibrosarcoma. It is not transplantable  into 
normal syngeneic mice, but  it  will  grow progressively in mice treated  with  subcarcinogenic 
doses  of UV light  (30-50 half-hour exposures).  The UV light  source is a  bank of six  FS-40 
Westinghouse fluorescent sun lamps (Westinghouse Electric Corp., Pittsburgh,  Pa.)  emitting 
principally 280-320 nm with a total energy output of 1.79 ×  10  a ergs/cm2/sec. RD-1024 is also 
maintained in vitro in alpha modified minimal essential medium (MEM; Flow Laboratories, 
Inc., Rockville, Md.) supplemented with 100 U of penicillin/ml,  100 #g of streptomycin/mi, 2 
mM glutamine  (Microbiological Associates,  Walkersville,  Md.)  and 5-10% fetal or newborn 
calf serum  (Flow Laboratories, Inc.; complete alpha MEM).  Over a  period of several years, 
RD-1024 has retained its morphological characteristics and exhibits stability with regard to its 
tumorigenicity. Hereafter, the mice in which this tumor and all regressor tumors are p~saged 
will be called UV-treated mice. 
Cloning of RD-1024.  RD-1024  growing in  a  UV-treated  animal  was  excised  and: finely 
minced before dissociation in a  solution of 0.1% collagenase plus 0.1  dispase in alpha MEM 
(-1 g of tissue/20 ml, at 37°(2 for 30 rain with stirring).  10 million viable cells were seeded into 
75-cm  2 plastic gelatin-coated tissue culture flasks (T-75; Corning Glass Works, Corning, N. Y.) 
and allowed to adhere for 48 h at 37°C in 6.5% CO2. After washing three times with phosphate- 
buffered  saline,  cells  were  trypsinized  with  a  dilute  trypsin  solution  (0.25%),  washed,  and 
counted. Cells were pipetted vigorously to ensure a fine single cell suspension, and suspended 
in a  0.33%  agarose solution  (Seaplaque;  FMC Corp~  Homer City, Pa.)  in  complete alpha 
MEM, and held at 42°C;  final cell  densities were  10,  10  a, and  102 cells/ml.  10 ml of these 
agarose cell suspensions were seeded onto the bottoms of 75-cm  2 tissue culture flasks over 0.66% 
agarose-alpha MEM sublayers. After gelification at room temperature, cultures were held at 
37°C  in 6.5% (202  and were fed every 5-7 d  with  10 ml of the warm 0.33%  agarose-alpha 1346  IN VIVO INTERACTION  OF ULTRAVIOLET  TUMOR VARIANTS 
MEM solution. Microscopically visible clumps appeared after 3 d  and became visible to the 
unaided eye within 2 wk. At 16 d, the flask seeded at 102 cells/ml contained 166 visible clones, 
the flask  seeded  at  10  a cells/ml contained 506  clones, and the flask  seeded  at  104 cells/ml 
contained too many to count. 12 well-isolated clones were picked at random by suction with a 
bent Pasteur pipette and each was placed into a well of a 24-well Costar plate (Coming Glass 
Works)  in 1.5 ml of complete alpha MEM. After 7-13 d, when ~50% confluency had been 
reached, the wells were trypsinized and the cells were transferred first to 25-cm  2, then into 75- 
cm  ~ tissue culture flasks.  50  million cells of each stable clone were  frozen in alpha MEM 
containing 10% dimethyl sulfoxide and 20-50% fetal bovine serum. 
Phenotypic Characterization of Clones.  Clones were evaluated for tumorigenicity  as described in 
the legend to Fig. 1. In addition to the parent regressor  tumor, RD-1024, one stable regressor, 
CI 8, and two progressor clones, CI 4 and CI 9, were chosen for further characterization. 
Cell doubling times for the various clones in vitro were determined by plating the tumor 
lines in 75-cm  2 flasks at 2 ×  10S/ml and incubating at 37°C in 6.5% COs for various lengths of 
time. After careful washing three times with phosphate-buffered saline, the remaining  cells were 
trypsinized and viable cells were counted. The number of doublings during a particular time 
period, t, was determined as the difference in the number of cells at time t minus the number 
of cells at the time of plating, expressed  as a function of log2. Doubling time is expressed  as the 
time in culture divided by the number of doublings occurring during that period. 
Plating efficiency was performed in triplicate in complete alpha MEM at two dilutions, 200 
and 400 ceils/ml. This parameter is expressed  as the average number of colonies visible after 10 
d divided by the number of cells seeded (× 100). 
Draining Lymph Node Cell (DLN) Assay.  Cytotoxic lymphocytes were generated as described 
in detail previously (14). Briefly,  mice were challenged in the hind footpads with tumor. 8 d 
later, the draining popliteal nodes were removed and put into culture. After 4 d, these effectors 
were cultured for 6 h with nlCr-labeled tumor cell targets. The supernate was then removed 
from each well and counted in a  Beckman Biogamma counter (Beckman Instruments, Inc., 
Fullerton, Calif.). Percent specific lysis is expressed  as: 
experimental counts -  control counts 
Percent specific lysis =  ×  100. 
maximum releasable -  spontaneous release 
For experiments in which unlabeled tumor cells were added as blockers of effector  activity, an 
effector:target (E:T) ratio of 25:1  was used, with blocker:target (B:T) ratios of 4:1, 2:1, and 
1 : 1. Percent inhibition is expressed as: 
percent lysis with blockers 
Percent inhibition =  100-  ×  100. 
percent lysis without blockers 
Gamma Irradiation of Mice.  Mice were irradiated with 500  tad of gamma irradiation in a 
Gammator (Isomedix, Parsippany, N. J.) containing a  lSTcs source.  Mice were held in 50-ml 
plastic centrifuge tubes and exposed at an exposure rate of 625 rad/min. This dose has been 
shown to abolish the capacity of mice to mount a primary anti-tumor response, in that UV 
regressor  tumors can grow progressively (12). 
Cross Immunization of Mice.  Mice were immunized by the subcutaneous injection of 5 X 108 
tumor cells in 0.1  ml of alpha MEM without serum. After 14-21  d, when the implants had 
been completely rejected, mice were challenged with either 10  e progressor cells freshly trypsin- 
ized from tissue culture, or with a 1-mm  s tumor fragment excised directly from a tumor-bearing 
animal. Tumor growth was evaluated weekly.  Nonimmunized animals served as controls for 
the growth of progressor tumor. 
Double Challenge of Mice.  Two methods were employed for the simultaneous challenge of 
mice with both regressor  and progressor cells. In the first, a mixed inoculum of viable, freshly 
trypsinized, single cells was inoculated subcutaneously on the shaved belly in 0.1 ml of alpha 
MEM  without  serum.  Tumor growth  was  monitored weekly.  The  second  method  was  by 
separate subcutaneous injection of regressor  and progressor cells at two different sites on the 
belly. Both implants in each  animal were evaluated weekly for tumor growth.  During the MARY  SCHMITT  AND  RAYMOND A.  DAYNES  1347 
period of evaluation (4 wk) the separate implants remained isolated from one another, or one 
or both were rejected completely. Cell numbers used for challenge are supplied in the tables. 
Results 
Characterization of Tumor Clones.  The UV regressor tumor RD-1024 is not tumori- 
genic when transplanted  into normal syngeneic mice. It was capable of progressive 
growth, however, in the autochthonous host and  in animals immunosuppressed by 
other  means.  Because  it  has  been  previously shown  (9)  that  one can  isolate both 
tumorigenic and nontumorigenic clones from tumor cells exposed in vitro to mutagens, 
we reasoned that  host  immune pressures or other genetic or environmental factors 
might also be able to cause the generation of tumor cell heterogeneity. Consequently, 
a  progressing tumor may contain subpopulations of tumor cells that differ from the 
parent  in tumorigenic potential, as has been shown by Dexter et al.  (16), and that 
perhaps clones can be isolated from a tumor that have increased tumorigenic potential 
as compared to the parent tumor. 
To test this hypothesis, RD-1024, a  UV regressor tumor, was excised from a  UV- 
treated tumor-bearing animal and cloned in soft agarose. Thus, the survival of clones 
was  dependent  upon  the  property  of anchorage  independence,  a  property  often 
accepted as a  correlate of cell transformation and tumorigenicity (17). After growth 
to semiconfluency in  liquid  medium,  each  clone was  injected into animals  for an 
evaluation of tumorigenicity phenotype. After 5  wk, the clones were judged  to be 
regressors or progressors. The regressor parent, RD-1024, grew in only one of the test 
animals; two of the test clones (CI 5 and C1 8) did not grow in any animals; and two 
clones (CI 4 and CI 9) grew progressively in the large majority of animals challenged 
with these tumors (Fig.  1). 
Because the possibility existed that  the two regressor clones did not grow for the 
simple reason that they were not tumors, C1 8 was injected into UV-treated and into 
500-rad-irradiated animals. It grew progressively in these immunocompromised hosts, 
establishing its categorization as a  tumor (Fig. 2).  (CI 5 had unfortunately been lost 
previously in tissue culture.) 
Three clones were evaluated in normal animals for possible dose-related tumori- 
genicity. C1 8 did not grow in any animals at any dilutions tested (5 ×  102-5 ×  107). 
C1 4  and CI 9 both grew progressively to the death of the host  in  100% of the test 
animals at  106 cells/mouse or greater (data not shown). In subsequent experiments 
with progressor clones, this dose (10  ~) was employed as a known tumorigenic dose. 
Morphologically, all three daughter clones appear similar  in  vitro, consisting of 
long,  thin,  spindle-shaped  cells  that  grow  in  a  semi-ordered  cordlike  array  until 
confluency, when they begin to pile up and form clusters on the monolayer surface. 
In this respect, they are all very much like the parent tumor, RD-1024. Cell doubling 
times are also similar among parent and clones: RD-1024, 27.5 h; C1 4, 29.3 h; CI 8, 
22.6 h; CI 9, 27.5 h. Plating efficieneies at low cell densities yielded disparate results 
among the cell lines: RD-1024,  11.6% CI 4,  12%; CI 8, 6.6%; CI 9, 22.2%.  Although 
these figures show wide variation, no correlation with tumorigenicity phenotype can 
be drawn. 
Cross-Reactivity of Clones and  Parent Tumor.  "Antigenicity"  per  se  has  long  been 
touted as the cause of growth or rejection of transplanted tumors, the less antigenic 
tumors (i.e., little disparity between host and tumor) growing progressively in second- 1348  IN VIVO  INTERACTION OF ULTRAVIOLET  TUMOR VARIANTS 
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Fro.  1.  Growth of RD- 1024 and daughter clones in vivo. Parent tumor and clones  were trypsinized 
at semi-confluency,  washed twice in alpha MEM without serum, and resuspended at a cell density 
of 5 ×  l0  s viable cells/ml (by trypan blue exclusion). 0.1 ml of each tumor cell suspension was 
inoculated subcutaneously onto the shaved bellies of five C3H mice (5 X l0  s cells/mouse). Tumor 
growth was measured weekly and is expressed as the mean of the product of two perpendicular 
diameters of a palpable tumor mass. •  -- CI 9 (growth in 5/5 mice), A =  RD-1024 (1/5), •  -- CI 
4 (4/5), [] = cl 5 (0/5), © = el 8 (0/5). 
ary hosts,  the more antigenic tumors being immunologically rejected by secondary 
hosts  (18).  The  expression  of tumor  antigens on  the  surface  of neoplastic cells  is 
presumably responsible for this phenomenon. Several mechanisms have been invoked 
to  explain  the  appearance  of  these  antigens:  reexpression  of  fetal  antigens  (19), 
expression  of altered  or  nonhistocompatible H-2  antigens  (20),  or  of neoantigens 
arising from some unknown stimulus. UV tumors are known to express both TSTA, 
antigens unique to each  tumor, and TAA, antigens expressed by all UV tumors in 
common (12). The TSTA seem to be the antigens against which the major rejection 
response is elicited, although TAA can also be demonstrated to function as rejection 
antigens (12). It thus seemed reasonable to test  for the presence of tumor rejection 
antigens on our clones and for the functional specificity of the response raised against 
these antigens during tumor challenge. The possibility existed that one could find a 
difference between regressor and progressor antigenic expression, either qualitative or 
quantitative. 1349 
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Fio. 2.  CI 8 in normal, 500 rad-, and UV-treated mice. CI 8 was trypsinized at semi-confluency, 
washed twice in alpha MEM without serum, and resuspended at a cell density of 10  ? viable cells/ 
ml. 0.1 ml of this suspension  was inoculated subcutaneously onto the bellies  of five normal, five 500- 
rad-irradiated, and five UV-treated C3H mice (10  e cells/mouse). Tumor area is expressed as the 
mean of the product of two perpendicular diameters of tumor growth as measured weekly for 4 wk. 
•  ~ normal animals, •  -- 500-rad-irradiated animals, O -- UV-treated animals. 
It was found that prior immunization with either the parent regressor tumor, RD- 
1024, or with C1 8, the regressor clone, protected against subsequent challenge with 
either progressor clone, CI 4 or CI 9 (Figs. 3 and 4; data shown for C1 4). These results 
suggested to us that  the immune apparatus recognized cell surface antigens on the 
challenge tumor similar to those present on the immunizing tumor. Had the parent 
been a  heterogeneous mixture of different subpopulations expressing different anti- 
gens, one might have expected less protection afforded by the parent than by CI 8, on 
purely statistical grounds. If the clones had possessed different rejection antigens, the 
challenge tumor would have progressed in spite of prior immunization  with regressor. 
Although these clones are phenotypicaUy different by the criterion of tumorigenicity, 
they nevertheless appear to possess similar or even the same TSTA as one another 
and as the parent tumor. 
Susceptibility  to Lysis by Cytotoxic T Lymphocytes (CTL)  Generated against Cl 8.  Because 1350  IN  VIVO  INTERACTION  OF  ULTRAVIOLET  TUMOR  VARIANTS 
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FIG. 3.  Parent RD-1024 protects against challenge with progressor. C3H mice were immunized 
with  RD-1024 cells, then  challenged  with  CI 4  cells as described  in  Materials and Methods. 
Nonimmunized  animals challenged with CI 4 served as controls. •  = CI 4 (6/6), A = CI 4 in RD 
1024 immune mice (2/6). 
immune recognition seemed to be operative in the preceding immunization-challenge 
experiments, and only cross-reactive antigens could be discerned, a  second, indirect, 
approach to the problem of antigen expression was attempted in the expectation that 
one might in some way be able to discriminate between progressor and regressor cell 
surfaces. 
In  vivo  experiments  in  our  lab  have  demonstrated  that  effector  cells  that  will 
recognize and cause the destruction of tumor in vivo can be generated by a  combi- 
nation of in vivo and in vitro manipulations (R. A. Daynes, unpublished data). When 
CTL  generated  against  a  particular  progressor  tumor  are  injected  simultaneously 
with that tumor into a test animal or intravenously at the same time as a subcutaneous 
tumor challenge, the CTL activity will result in the rejection of the tumor cells. The 
tumor will grow normally in control animals. 
Similarly, by using in vitro analysis, there exist means to assess the susceptibility of 
tumor cells to iysis by effector cells (CTL)  generated against a  particular tumor.  If 1351 
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Fio.  4.  Regressor C1 8 protects against challenge with progressor. C3H mice were immunized with 
Cl 8 cells,  then challenged with Ol 4 cells  as described in Materials and Methods. •  -- Cl 4  (6/6), 
A  ----- CI 4 in Cl 8 immune mice (2/5). 
target epitopes on progressor and regressor cells differ, either qualitatively or quanti- 
tatively, a  standard 51Cr release assay can be used to detect these differences, and to 
establish whether equivalent sensitivity to lysis by effector lymphocytes exists among 
progressor  and  regressor  clones.  Footpad  challenge  of mice  with  CI  8  tumor cells 
results 8 d  later in DLN that will differentiate into CTL during an additional 4 d  of 
in vitro culture.  The amount of specific lysis of labeled target tumor cells by these 
CTL can be expressed as a function of 51Cr released upon 6-h incubation of cultured 
DLN  with  51Cr-labeled  tumor targets.  Using  this  assay,  the  parent  tumor and  all 
clones were susceptible to lysis to the same degree, again suggesting the presence of a 
similar target determinant on all clones, which is recognized by CTL with functional 
specificity for C1 8 only (Table I). 
Epitope  density  was  also  considered  to  be  a  possibly  significant  parameter  for 
discrimination between regressor and progressor clones. Target determinants for CTL 
can  be titrated  by employing a  variation on  the  basic 51Cr release assay, with  the 
addition  of unlabeled  tumor cell blockers at  several dilutions  to compete with  the 1352  IN  VIVO  INTERACTION  OF  ULTRAVIOLET  TUMOR  VARIANTS 
TABL~  I 
Lysis of RD-1024 and Daughter Clones by Anti-Cl 8 DLN 
Percent spe-  Effector cells*  Target cellsJ~  E:T ratio  cific lysis§ 
C3H anti-CI 8  CI 8  50:1  70.7 
25:1  52.1 
12.5:1  24.0 
C3H anti-Cl 8  RD- 1024  50:1  65.6 
25:1  57.1 
12.5:1  29.1 
C3H anti-Cl 8  CI 4  50:1  88.2 
25:1  72.9 
12.5:1  51.1 
C3H anti-Cl 8  C1 9  50:1  60.9 
25:1  42.8 
12,5:1  37.2 
* 4-d-old cultured popliteal lymph node cells from 8-d immunized C3F1  mice. 
~: 104 StCr-labeled  cells per  microtiter  well  in  a  total  volume of 200  ml  of 
complete alpha MEM. 
§ Percent  specific lysis of nlCr-labeled targets was calculated as described in 
Materials and Methods. 
TABLE  II 
Cold Cell Inhibition of Lysis of5lCr-labeled Cl 8 Targets 
Percent  Percent 
Target  Blocker cells§  specific  inhibi-  Effector cells*  cellsqk  tion of 
lysisll  lysisl  [ 
C3H anti-Cl 8  121 8  --  53.3  -- 
C3H anti-Cl 8  CI 8  C1 8 
4:1  26.9  49 
2:1  39.8  25 
I : 1  42.0  22 
C3H anti-Cl 8  C1 8  RD-1024 
4:1  18.8  65 
2:1  27.4  49 
1:1  37.7  29 
C3H anti-Cl 8  (31 8  CI 4 
4:1  15.7  70 
2:1  25.4  52 
1 : 1  37.8  29 
C3H anti-Cl 8  CI 8  CI 9 
4:1  19.3  64 
2:1  35.6  33 
1:1  44.4  17 
* 4-d-old cultured popliteal lymph node cells from 8-d immunized C3H mice. 
E:T ratio, 25:1. 
~: 51Cr-labeled targets at  104 cells/200-ml well 
§ B:T ratios of 4:1, 2:1,  1  : 1. 
[I Percent  specific lysis and percent  inhibition of lysis of ~tCr-labeled  targets 
were calculated as described in Materials and Methods. MARY SCHMITI" AND RAYMOND A.  DAYNES  1353 
labeled targets. CTL activity toward the labeled cells will be inhibited and released 
5XCr will be proportionally decreased. When this assay was performed, inhibition of 
lysis was observed for all clones  and  for the parent  (Table II). This inhibition  was 
titratable, and similar among all test groups. Two different combinations of targets 
and DLN yielded the same results (anti-Cl 8 DLN on 51Cr-labeled CI 8 targets, and 
anti-Cl 9 DLN on ~lCr-labeled CI 9 targets), with all clones and the parent used as 
blockers (data are shown for anti-Cl 8  DLN on 51Cr-labeled CI 8  targets). Thus, in 
our hands, tumorigenic and nontumorigenic clones seem to express similar antigens, 
in similar quantities, and are equally sensitive to lysis by CTL, at least as detected by 
assays that measure in vivo antigenic recognition or in vitro cytotoxic activity. 
Regressor Cells Influence the Tumorigenicity Phenotype of Progressor Clones.  The parent 
tumor,  RD-1024,  used  in  these studies  is a  regressor tumor, and  does not  grow  in 
normal secondary transplant hosts.  Nevertheless, both progressor and regressor sub- 
populations were isolable from the tumor, and were presumably present in the tumor 
before excision. In consideration of the data that suggest that the growth of cells in a 
semisolid medium correlates with tumorigenicity, we concede that  the cloning pro- 
cedure may have enhanced the isolation of clones of the progressor phenotype, and 
that statistically, the relative numbers of regressor and progressor clones obtained by 
this method may not reflect the actual composition of the tumor. Still, the question 
remains: why is RD-1024  a  regressor? If tumorigenicity implies a  lack or a  decrease 
in  growth  control,  why  haven't  the  progressor clones  become dominant  in  such  a 
tumor mass? At some level of regulation, some mechanism must effectively prevent 
the expression of the progressor phenotype. The results of the cross-reactivity experi- 
ments  suggest  an  immunological  basis  of control.  Immunoregulation  might  be  a 
consequence of the absolute numbers of progressor and/or regressor cells, or possibly, 
of the  relative  ratios  of progressor  to  regressor cells,  or  possibly of the  sequential 
appearance  of the  two  phenotypes  during  tumor progression.  By manipulation  of 
these parameters, one might be able to influence the ultimate tumorigenicity pheno- 
type of a  tumor implant. 
In  an  attempt  to  discover  whether  the  progressor  phenotype  would  be  able  to 
predominate  at  some  ratio  of  regressor  to  progressor,  we  constructed  composite 
"tumors," consisting of known proportions of regressor and progressor cells. A known 
tumorigenic dose (106) of progressor cells was mixed with varying doses of regressor 
cells.  Groups of mice were  inoculated  with  these  mixtures  and  tumor  growth  was 
monitored.  Singly challenged  controls  were  injected  with  the  same doses of either 
progressor or regressor cells.  The results of this experiment are shown in Table III. 
Mice  injected only with  regressor cells rejected the tumor;  C1 8  is nontumorigenic, 
therefore,  at  all  doses  tested.  Mice  injected  with  progressor  cells  alone  showed 
progressive growth of the tumor. All groups of test animals that were injected with 
both regressor and progressor cells rejected the challenge doses. Even low numbers of 
regressor  cells,  i.e.,  a  regressor:progressor  ratio  of  1:10,  resulted  in  the  regressor 
(parental) phenotype. 
To address the question of the nature of the influence, whether direct or indirect, 
that  the regressor exerted over the progressor, we initiated  a  second experiment  in 
which regressor and progressor cells were injected simultaneously but separately into 
two different  sites on  the bellies of the test  mice. The outcome was essentially the 
same as was observed in the mixed challenge, with the progressor control group being 1354  IN  VIVO  INTERACTION  OF  ULTRAVIOLET  TUMOR  VARIANTS 
TABLE  III 
Mixed Challenge with Regressor and Progressor Cells 
Group 
Challenge* 
CI 8  CI 4 
Tumor  Incidence  size:~ 
A  Normal mice 
B  Normal mice 
C  Normal mice 
D  Normal mice 
E  Normal mice 
F  Normal mice 
G  Normal mice 
H  Normal mice 
I  Normal mice 
106 
5X 106 
10  e 
5 X 106 
105 
5 ×  106 
106 
5x  l0  s 
106  0/5 
to"  0/5 
10  s  0/5 
10  s  1/5  13.5 
10  s  4/5  139.3 
0/5 
0/5 
0/5 
1/5  1.8 
* Tumor cells were  administered subcutaneously on  the belly in 0.1  ml  of 
alpha MEM without serum. 
:~ Tumor size  is expressed as the mean of the products of two perpendicular 
diameters of tumor growth. 
TABLE  IV 
Double Challenge with Regressor and Progressor Cells 
Group 
Challenge*  Incidence  Tumor size:~ 
CI 8  CI 4  CI 8  CI 4  CI 8  CI 4 
Experiment 1 
A  Normal C3H  106  106 
B  Normal C3H  5 ×  105  10  s 
C  Normal C3H  106  10  s 
D  Normal C3H  5 ×  10  s  106 
E  Normal C3H  106 
F  Normal C3H  10  5 
G  Normal C3H  5 x  10  e 
H  Normal C3H  10  s 
I  Normal C3H  5 ×  106 
Experiment 2 
A  500-rad treated§  106  106 
B  Normal  t0  s  l06 
C  Normal  106 
D  Normal  10  n 
0/5  1/5 
0/5  0/5 
0/5  0/5 
0/5  0/5 
4/5 
0/5 
0/5 
0/5 
0/5 
15.0 
67.7 
4/5  5/5  77.7  185.5 
1/5  0/5  3.2 
4/5  172.1 
1/5  5.0 
* Tumor cells were administered subcutaneously on the belly in 0.1 ml of alpha MEM without serum; CI 
8 on the left, CI 4 on the right. 
:[: Tumor size is expressed as the mean of the products of two perpendicular diameters of tumor growth. 
§ Mice were treated with 500 rad of gamma irradiation 24 h before challenge with tumor. 
the only group  of animals  growing the tumor  (Table IV, experiment  1). The  fact that 
challenge  in two  sites brings  about  the same  result,  as  does  challenge with  a  mixed 
inoculum,  suggests that  these effects are indirect and  that they are mediated  by some 
cell or substance other than the tumor  itself. When  500-rad-irradiated  mice are doubly 
challenged  with  both  regressor  and  progressor  cells,  tumor  masses  develop  at  both 
sites  of  injection,  whereas  normal,  untreated  mice  reject  both  inocula  (Table  IV, 
experiment  2). Because treatment  of mice with 500 rad of gamma  irradiation is known 
to abrogate  the ability of mice to mount  a  primary  anti-tumor  response,  leaving the MARY  SCHMITI"  AND  RAYMOND  A.  DAYNES  1355 
secondary response intact, these results further reinforce the idea of an immunological 
mechanism of tumor rejection. 
Discussion 
A  neoplasm,  like  a  parasite,  must  possess  a  means  of overcoming host  defense 
mechanisms in order to lose its sensitivity to normal tissue regulatory constraints. If 
immunosurveillance is a valid concept, then expansion of a neoplastic cell population 
depends  either upon  the  breakdown  of the  surveillance system  itself or  upon  the 
emergence within the tumor of some mechanism that permits the neoplastic cells to 
proliferate in spite of host regulation. In parasites, these "games" of evasion (21) have 
developed over evolutionary time. A  primary tumor, however, has only one oppor- 
tunity to express the neoplastic phenotype, so its persistence indicates a  more rapid 
means of escape from host control, one that can be developed over the course of a 
limited number of cell doubling times. In fact, the concept of tumor progression is 
centered around the evolutionary capabilities of a neoplasm, in particular, or around 
the emergence of increasingly tumorigenic variants that possess a growth advantage 
over existing subpopulations within a tumor or, alternatively, possess means to better 
evade host defense mechanisms, immune or otherwise (22). 
Although a  monoclonal origin has been assumed for the great majority of tumors 
and has been convincingly shown for several tumors (monoclonal spike in myelomas 
and single G-6-PD isoenzyme in tumors arising in heterozygotes), most tumors are 
heterogeneous in a number of phenotypic characteristics. Morphology, histology, and 
karyotype  often  show  evidence  of heterogeneity  within  individual  tumors  (1-3). 
Hormone sensitivity, drug resistance, metastatic potential, and growth kinetics have 
all been demonstrated to be heterogeneous among tissue culture lines derived from 
tumors  by  artificial  selection  pressures  (6-8).  Immunological  non-cross-reactivity 
between tumor fragments excised from different areas of the same fibrosarcoma can 
be added to this compendium of phenotypic variant  types  (23).  Elegant statistical 
analysis of parent  and  clonal lines has suggested the  probable preexistence of this 
heterogeneity in vivo, at  least in regard to the formation of lung foci in a  popular 
metastasis model (8, 24). 
It is possible that some of these variants simply represent components of the myriad 
life support systems available to the tumor as it grows, and are not actually included 
in the neoplastic cell population. Alternatively, minor subpopulations may represent 
neoplastic variants  that  lead  a  cryptic existence within  the  tumor,  but  are  totally 
irrelevant to the growth or non-growth of the incipient tumor. Finally, phenotypic 
variants may play an obligate role in tumor progression, and it is to this end that 
heterogeneity within tumors is generated, that is, to enhance the progressive growth 
of neoplastic cells within primary tumors. 
Tumors induced in mice by treatment with UV radiation are unique in that the 
majority  of these  tumors  will  not  grow  when  they  are  transplanted  into  normal 
syngeneic hosts. These UV regressor tumors progress, however, when they are trans- 
planted into recipients previously treated with subcarcinogenic doses of UV light, a 
known  immunosuppressive  agent.  Using  adoptive  transfer  protocols,  it  has  been 
shown  that  UV-treated  animals  possess  suppressor  T  cells  (T,)  with  functional 
specificity for the common antigens (TAA) on UV tumors. This T8 population must 
have  arisen  in  conjunction with  and  consequent  to  UV  irradiation,  because  it  is 1356  IN VIVO INTERACTION OF ULTRAVIOLET TUMOR  VARIANTS 
present  in  UV-treated  animals  that  have  never  undergone  tumor  challenge.  By 
extension to the primary host, it has been postulated that the preexistence of this Ts 
response generated by UV light is responsible in part for the emergence of skin tumors 
in chronically irradiated animals (25). Thus, it appears that UV light possesses  both 
immunosuppressive  and  carcinogenic  activity  in  an  irradiated  host,  and  that  the 
former precedes the latter. There are theories that deal with the actual mechanisms 
giving rise to suppressive activity in UV-treated animals  (26). For our purposes, we 
shall simply assume that such suppression is present and functioning in these animals. 
Our interest in this phenomenon extended beyond Ts cells, however, and beyond 
the implications that the function of this subset of regulatory cells may have for the 
host's perception of tumor. We felt it might be useful to scrutinize the tumor itself for 
insight into this dichotomous situation where a UV tumor grows in the primary host 
hut not in normal syngeneic transplant hosts. Other investigators (9,  10) using other 
systems have been able to generate tumor variants with differing grades of tumori- 
genicity, apparent upon transplantation into appropriate hosts. These model systems 
all include mutagenesis or chemical or viral carcinogenesis to facilitate detection and 
isolation of cell lines differing in tumorigenicity phenotype. In light of the heteroge- 
neity  that  has  been  observed  in  tumors,  we  considered  the  possibility  that  these 
variants might reside in vivo within virgin UV tumors, and that they could be isolated 
by standard cloning techniques. 
The cloning of one of these UV regressor tumors in soft agarose has resulted in the 
isolation of stable clones that exhibit heterogeneity of tumorigenicity phenotype. C1 
8 does not grow in normal syngeneic mice at any tested tumor dose. C1 4 and CI 9 
both grew when they were inoculated at a dose of l0  s cells/mouse or greater. We have 
shown that these clonal subpopulations are immunologically cross-reactive, and that 
a  rejection  response  elicited  toward  a  regressor  clone  can  be  responsible  for  the 
secondary or concomitant rejection of a  progressor clone. Preliminary findings also 
suggest  that  regressor cells are capable of initiating an  activity that  results  in  the 
rejection of an 8-d implant of progressor tumor (data not shown). In this case, positive 
effector activity elicited by the regressor was capable of overriding any suppressive 
activity established by implantation of progressor tumor 8 d earlier. Experiments are 
underway to explore the limits of this regressor-induced activity, with respect to the 
interval between progressor and regressor challenge.  It is possible that  the positive 
effector activity induced by the regressor is not absolute. At more extended intervals, 
or possibly at shorter intervals, between progressor and regressor challenge, one may 
find the regressor cells incapable of prevailing over existing suppressive mechanisms 
active in  a  progressor tumor-bearing animal,  resulting in continued growth of the 
progressor tumor. A second possibility would be progressive growth of both regressor 
and  progressor  implants,  implying  an  upset  in  the  balance  between  positive  and 
negative immunoregulatory activities. 
Assuming that both regressor and progressor subpopulations existed in the original 
tumor, and that they are also present in the transplant, one must conclude that the 
presence of regressor cells in a  heterogeneous transplant suppresses in some manner 
the expression of the progressor phenotype. We have shown that cytotoxic cells can be 
generated against the regressor population that act in vitro to kill related tumor cell 
clones in a  cross-reactive manner. In all probability, it is this effector function that 
results in the elimination of a tumor implant in a normal animal, despite the presence MARY SCHMITT AND RAYMOND A. DAYNES  1357 
within the implant of cells with progressive growth potential. In a UV-irradiated host, 
the preexisting regulatory T, cell population prevents the generation (or the expres- 
sion)  of a  positive  effector response  and  a  transplant  can  assume  the  progressor 
phenotype.  A  UV  tumor  in  UV-treated  hosts  retains  its  heterogeneity, however, 
because after excision from a  UV tumor-bearing animal and transplantation  into a 
normal animal, the original regressor phenotype is reestablished. The same suppressor 
mechanism may have been operative in the primary, autochthonous host, in that UV 
light caused the expansion ofa T, cell population with specificity for the cross-reactive 
antigens on UV tumors, such that no effective positive cytotoxic response could be 
raised against the incipient neoplasm, and it grew progressively as a  tumor, though 
populated with both regressor and progressor cells. 
The fact that regressor Cl 8 shows antigenic disparity with the host and that CI 4 
and  Cl  9  possess the same  disparity,  although  they are tumorigenic, suggests  that 
antigenicity is perhaps not the ultimate criterion for growth or rejection of a  tumor 
implant,  or by extension,  for tumorigenicity in  a  primary  host.  Our  experiments 
suggest  that  positive or  negative  immunoregulatory  responses  can  be  elicited  by 
individual clones of cells. We would propose that a balance between these activities 
exists within a tumor-bearing animal, and that heterogeneity within a tumor contrib- 
utes significantly to the immune perception of the host to the tumor, and thus also to 
the final outcome of the host-environment-tumor interaction. 
Summary 
We have shown that both regressor and progressor clones can be isolated from a 
UV regressor tumor, RD-1024.  Although  the daughter clones are characterized by 
differences in  tumorigenic potential  in  normal  transplant  hosts,  they nevertheless 
seem to express the same major tumor rejection antigens, because immunization with 
either the regressor parent tumor, RD-1024, or with regressor C[ 8  protects against 
subsequent  challenge  with  progressor  C1  4  or  Cl  9.  Consistent  with  the  in  vivo- 
generated  data  is  the  evidence  that  draining  lymph  node  cells  with  functional 
specificity for regressor Cl 8  are capable of cross-reactive cytotoxicity in an in vitro 
chromium release assay. 
We have demonstrated an indirect interaction occurring in vivo between regressor 
and progressor cells, in that Cl 8 cells have the ability to influence the outcome of 
simultaneous  or sequential  challenge with  Cl  4  or Cl  9  cells.  Because  500  rad  of 
gamma irradiation has been shown to compromise the ability of mice to respond to 
a  primary challenge with tumor, an immunological mechanism is implicated in the 
ultimate rejection of progressor tumor in a doubly challenged host. 
The  importance  of  these  results  lies  in  the  knowledge  that  these  interacting 
subpopulations have been isolated directly from a tumor growing in vivo and that no 
selection pressure has been exerted on the cells greater than the short in vitro culture 
period necessary for the isolation and expansion of individual clones. The apparent 
immunoregulatory potential in a tumor-bearing animal is thus seen to be modified in 
accordance with the phenotypic heterogeneity of the cells within that tumor. 
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